Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine.

NPJ Breast Cancer · 2017 · PMC5445616 · PMID 28649643

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Similarly, for patients identified as high-risk, we observed no statistically significant difference in DRFS between HER2-positive or HER2-negative patients ( p = 0.09), although we did observe that HER2-positive patients showed a trend for worse outcome.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.